SQI Diagnostics Announces Stock Option Grants

The options were granted at an exercise price of $1.50. Pursuant to thepreviously approved stock option plan, the options have a term of 5 years andvest over a 18 month period.

About SQI Diagnostics

SQI Diagnostics is a medical systems automation company focused onevolving laboratory-based biomarker testing. Using automation and proprietaryminiaturization technologies, SQI Diagnostics significantly improves theeconomies of scale for laboratories performing multiple biomarker testing athigh volumes, allowing them to deliver patient results faster using less laborand fewer resources. SQI Diagnostics' initial products target the $1.4 billionautoimmune disease market, with initial products for Rheumatoid Arthritis andThrombosis. SQI Diagnostics is based in Toronto, Canada. For furtherinformation please visit .

Certain information in this press release is based on beliefs andassumptions of the Company's senior management and information currentlyavailable to it that may constitute forward-looking information within themeaning of securities laws. Such statements reflect the current views of theCompany with respect to future events and are subject to certain risks anduncertainties. Actual results, events, and performance may differ materially.Readers are cautioned not to place undue reliance on these forward-lookingstatements.

    This release was prepared by management of the Company who takes full    responsibility for its contents. The TSX Venture Exchange has not    reviewed and does not accept responsibility for the adequacy or accuracy    of this news release.

For further information

Chief Financial Officer, Andrew Morris, (416)674-9500 ext. 229, amorris@sqidiagnostics.com
Investor Relations, JamesSmith, (416) 815-0700 ext. 229,